image credit- shutterstock
France headquartered Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, and US-based startup Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership.
As part of the collaboration, Sartorius will invest up to $3 million in a minority shareholding in Nanotein Technologies to support the commercialisation and joint development of solutions based on its NanoSpark® platform.
Under the exclusive distribution agreement, Sartorius will offer Nanotein’s lead products to customers worldwide: the NanoSpark® STEM-T Soluble T Cell Activator and NanoSpark® GROW-NK Soluble Activator. These reagents are designed to enhance the expansion and quantity of T cells and natural killer (NK) cells – two key immune cell types used in a range of cell therapy applications, including CAR-T and NK-based cancer therapies.
Producing effective cell therapies begins with the activation of immune cells to trigger expansion and generate large numbers of high-quality cells. In the process, developers face challenges such as the reliance on feeder cells or inconsistent yields.
In addition, Sartorius Stedim Biotech and Nanotein Technologies will collaborate using the NanoSpark® platform to develop additional novel product offerings for the rapidly expanding cell and gene therapy markets.
